Gaucher Disease Drugs Market Projected To Grow At A CAGR Of 1.1% For The Forecast Period From 2018 To 2025 : Grand View Research Inc.
San Francisco, 10 September 2019: The Report Gaucher Disease Drugs Market Size, Share & Trends Analysis Report By Type, By Therapy (Enzyme Replacement Therapy, Substrate Replacement Therapy), By Major Markets, And Segment Forecasts, 2018 – 2025 The global gaucher disease (GD) drugs market size is expected to reach USD 1.71 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 1.1% during the forecast period. Growing prevalence of the disease and increasing research and development activities in the field are likely to help the market in gaining momentum over the coming years. With high unmet needs, there is a strong need for development of novel treatments with improved efficacy in neuronopathic complications, convenient dosage, and reduced cost. Gaucher disease is a genetic metabolic disorder, caused by mutations in GBA gene. People with Gaucher disease produce low glucocerebrosidase (GCase), an enzyme required to degrade glucocere